Capecitabine induced toxicities such as hand-foot syndrome (HFS) and progression of metastatic cancer are both treatable with concurrent celecoxib as shown in the ADAPT (Activating Cancer Stem Cells from Dormancy And Potentiate for Targeting) trial. In the present study, five commonly used NSAIDs, including celecoxib were compared for their pro-oxidative capacities as cytotoxic drugs against human and mouse metastatic melanoma or breast cancer cells in vitroand the source of cellular ROS production induced by celecoxib was examined in greater detail. Results: Celecoxib was unique among the NSAIDs in that it showed particular potency as a cytotoxic drug against the metastatic cancer cells with IC 50 values in the low micromolar range. Celecoxib rapidly enhanced mitochondrial superoxide production in situ from cancer cells within minutes, leading to a decrease in cellular respiration and dissipation of the mitochondrial transmembrane potential (Δψ m ), followed by extensive ROSdependent apoptosis of the metastatic cancer cells. Celecoxib also showed rapid and direct effects on isolated mitochondria, inducing extensive ROS production in a dose-dependent manner, whilst it inhibited respiration via Complex I or Complex II when tested in whole cells. Mitochondrial ROS production was necessary for the celecoxib induced cell death. Innovation and Conclusion: These novel findings for direct effects of celecoxib on mitochondria to induce metastatic cancer cell death via a ROS-dependent pro-oxidative mechanism provide supportive evidence for its combinatorial use as a chemosensitizing agent complementing chemotherapies to improve response rates in patients with advanced metastatic cancers.
Introduction
Mitochondria in metastatic cancer cells differ markedly in their metabolism from the majority of primary cancers and normal cells [reviewed in [1, 2] ]. Metabolic changes in mitochondria have been established as causing an enhanced pro-oxidative state with increased ROS production leading to cancer cell invasion, migration and metastasis [3] [4] [5] . In a dynamic process involving hypoxic stress, cancer cells evolve and progress to greater malignancy with higher ROS levels promoting greater metastasis [6, 7] . However, high ROS levels are generally detrimental to cells, and the redox status of cancer cells differs from that of normal cells, such that cancer cells exhibit elevated ROS, which enables oxidative stress to work as an anticancer strategy [8] .
Many cells die from these stressful conditions, but the survivors, undergoing dramatic shifts in redox status with mitochondrial and nuclear damage from ensuing oxidative stress, promote further malignancy and metastasis [6, 9] . This selection pressure, promoted by the combined stressful conditions of hypoxia plus hypoglycaemia [10] involves dysfunctional mitochondrial ATP synthesis (i.e., oxidative phosphorylation; OxPhos), causing enhanced release of ROS as a byproduct of an impaired respiratory chain, which then causes mutations, particularly in the adjacent susceptible mitochondrial DNA, and eventually enhances metastasis [11] [12] [13] [14] . As a consequence, cytosolic Ca 2+ levels become elevated which helps trigger epithelial-mesenchymal transition, accelerated growth and invasiveness together with the emergence of more highly metastatic cancer stem cells [15] . ROS also stabilize the transcription factor HIF-1α [16] which up-regulates mRNAs encoding several key proteins involved in angiogenesis, cellular proliferation, erythropoiesis, vascularization and glycolysis [17, 18] .
These changes to metastatic cancer cells clearly link their greater pro-oxidative states with greater malignancy [6] and present targets for drugs such as NSAIDs to help eliminate cancers [19] . The mitochondrial pro-apoptotic or intrinsic cell death pathway can be activated by promoting increased ROS to reach excessive levels that lead to apoptosis via the opening of the mitochondrial membrane permeability transition pore complex [19] .
Longitudinal studies of patients using low levels of NSAIDs as analgesics over periods of many years have consistently shown a decrease in cancer incidence by 30%-50% when compared to the non-drug user and general population [20] [21] [22] [23] , suggesting that NSAIDs may be effective in lowering risk of metastasis [24, 25] . Although the NSAIDs are not commonly considered as anticancer drugs, they can selectively promote the intrinsic pathway of apoptosis in metastatic cancer cells [19] and affect mitochondrial function [26] . Unlike metastatic cancer cells with their highly pro-oxidative state, the normal cells can resist the effects of NSAIDs because they contain higher levels of anti-oxidant defences such as reduced glutathione, catalases, peroxidases, superoxide dismutases, glyoxylases and other ROS reducing enzymes (reviewed in [19] ).
In this study, five NSAIDs have been examined for their cytotoxic activity against metastatic breast cancer and melanoma cells. Surprisingly, celecoxib showed the most potent anti-cancer activity among these drugs, affecting mitochondrial function and inducing rapid and significantly higher levels of superoxide production leading to cell death. These pro-oxidative properties and direct effects on mitochondria directly correlated with the cytotoxic activity of the NSAIDs and their ability in the micromolar range to induce extensive metastatic melanoma and breast cancer cell apoptosis. Mitochondrial ROS was shown to be an essential mediator for the activation of apoptosis in metastatic cancer cells.
Materials and methods

Materials 2.2. Tissue culture
All cell lines were sourced from the American Tissue Type Collection (ATCC) and authenticated by MHC or HLA surface markers. Murine melanoma B16F10 cells and 4T1 cells were maintained in DMEM and RPMI respectively, supplemented with 6% heat-inactivated FBS, 4% heat-inactivated NBCS, Penicillin/Streptomycin, 1.6 mM Lglutamate, supplemented with 1% Glutamax and 20 mM HEPES buffer and incubated at 37°C in a humidified atmosphere of 5% CO 2 . Triple negative MDA-MB-231 and MDA-MB-468 breast, HeLa cervix, MCF-7 breast human cancers and NIH3T3 mouse fibroblast were grown in DMEM (Gibco; Rockville, MD, USA) supplemented with 10% FBS and incubated in 5% CO 2 at 37°C. Cells were harvested via trypsinisation (Gibco) after washing twice with 1 × PBS, and pelleted via centrifugation at 1250 rpm for 4 min. Cell counting and viability was determined using trypan blue dye exclusion.
Drug solubilisation
All drugs used were solubilised as a standard stock of 25 mM. Salicylate and diclofenac were solubilised in d.d·H 2 O. Celecoxib, nimesulide and sulindac were solubilised using a 100 mM stock solution of (2-Hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich). Solubilisation of celecoxib was also performed in DMSO 30%/ethanol 70%. Turbidity analysis at λ = 500 and 600 nm, revealed no crystal formation in 10 mM stock solutions. The maximal amount of vehicle DMSO/ethanol used (20-30 μL) was assayed in respiration, Δψm and cellular proliferation experiments alone compared to control with no apparent effect by vehicle.
Determining cytotoxic IC 50 values
Initially, the in vitro screening of the five NSAIDs tested for their cytotoxic activity against cancer cells was examined over a range of concentrations from 0 to 1 mM. The aim was to find those with potency in the low micromolar range, providing the rationale for further examining their off target activity on mitochondria, given previous findings with NSAIDs [26] and our preliminary evaluation of the literature reviewed in [19] . For each NSAID tested on the cell lines, the cytotoxic IC 50 values were determined using 96-well black wall, flat bottomed plates (Corning). Cell death was determined (A) with the use of Sytox green (Thermofisher Scientific) at a final concentration of 500 nM to differentiate viable from non-viable cell populations. Plates were read on a Flexstation 3 (Molecular Devices) spectrophotometer every 24 h for a total of 72 h; and (B) by using the MTT assay. IC 50 
Apoptosis
Apoptosis was determined using the FITC-Annexin V Apoptosis Detection Kit (BD Biosciences) following the manufacturer's protocol. Cells were seeded into 6-well plates at a density of 2 × 10 5 cells per well and incubated for 24 h before adding NSAIDs at the appropriate concentration and incubated for the indicated amount of time. Stained cells were then placed on ice and analysed using a BD Fortessa flow cytometer. Acridine Orange staining was performed in triplicate after incubating cells for 3 h in 100 μM celecoxib and stained for 15 min at 2 μg/mL before imaging on an Olympus IX53 microscope. Shift in fluorescence signals from excitation/emission maxima of 502/525 nm to 460/650 nm in the lysosomes was examined. For caspase 3/7 activation the Caspase-Glo 3/7 reagent from Promega was used following the manufacturer's protocol after incubation with celecoxib (at 100 μM to ensure significant activation of caspase occurred) and for the times as indicated.
Mitochondrial transmembrane potential (ΔΨ m ) in isolated cancer cells
Mitochondrial transmembrane potential (ΔΨ m ) was assayed by staining cells with rhodamine 6G (0.25 µM) before monitoring changes in fluorescence of whole cancer cells treated over the responsive range of celecoxib concentrations (0-20 μM) compared to untreated control cells (set as 100%). The changes in ΔΨ m were monitored with a Shimadzu spectrofluorophotometer (RF-5301PC; Tokyo, Japan) at 480 nm (excitation) and 565 nm (emission) wavelengths. The maximal change in magnitude of the fluorescence signal for ΔΨ m was determined by comparing ΔΨ m before and after dissipation with the protonophore CCCP (5 µM) at the end of each experiment (Hernández-Reséndiz et al., 2015).
Determining mitochondrial and cytosolic ROS production
Mitochondrial superoxide was measured using the MitoSOX™red kit (Life Technologies) and staining following the manufacture's protocol. Cells were seeded at 2 × 10 5 in 6-well plates and incubated for 48 h. /mL) were prepared, stained for 10 min at 37°C, with periodic gentle vortexing and then stored at 4°C before analysis. Immediately prior to analysis, cell samples were warmed to 37°C in a water bath for 60 s and baseline readings obtained before adding drug and continuously reading every 6 min.
The rate of H 2 O 2 production was also assessed by using Amplex Red (Invitrogen) in the presence of an excess of peroxidase [27] . AS-30 D isolated mitochondria (0.2-0.45 mg protein/mL) were incubated at 37°C in the KME-Pi buffer with 4-5 μM Amplex Red and 5 U/mL horse radish peroxidase (Sigma); the absorbance difference at 573 minus 595 nm was determined using a dual-beam spectrophotometer (2501PC, Shimadzu, Japan).
2.8. Mitochondria isolation from rat AS-30D hepatoma, heart and liver tissue.
For AS-30D mitochondria isolation, the digitonin permeabilization procedure was performed as previously described [28, 29] . The final mitochondrial pellet was washed with SHE (Sucrose 250 mM, HEPES 10 mM, EGTA 1 mM pH 7.4) buffer and incubated with 0.5% (w/v) fatty acid free-albumin and 1 mM ADP for 15 min at 4°C before final centrifugation.
Rat liver [30] or heart [31] mitochondria were isolated using the sequential centrifugation method as described previously. For rat heart mitochondria isolation, Nagarse (Sigma Chem.) was used at 6 mg per 4 hearts for a digestion time of 8 min on ice. The mitochondrial pellet was resuspended in SHE buffer at 50-80 mg protein/mL.
Oxygen consumption and OxPhos flux in isolated mitochondria and cells
For isolated mitochondria, respiration of AS-30D, heart and liver mitochondria (0.5-1 mg protein/mL) was assayed using an oxygraph with a Clark-type O 2 electrode in KME (120 mM KCl, 20 mM Mops, 1 mM EGTA) buffer pH 7.2 with 2 mM KH 2 PO 4 , and in the presence of different oxidizable substrates (as indicated in Results section) at 37°C. Drugs were added to the medium before mitochondrial addition. Mitochondrial state 3 respiration was stimulated with 600 nmol ADP.
For OxPhos, cells were incubated in Krebs-Ringer (125 mM NaCl, 5 mM KCl, 25 mM HEPES, 1.4 mM CaCl 2 , 1 mM KH 2 PO 4 , 1 mM MgCl 2 , pH7.4) buffer in the presence of glucose (5 mM) at 37°C. Drugs were added to the medium before cell addition. OxPhos flux was determined by measuring the oligomycin (5 µM) sensitive respiration with a Clarktype O 2 electrode as previously described [32] .
Microscopy
All fluorescence and light field microscopy was performed using an Olympus IX50 microscope and cellSens software (Olympus 33,342 for 10 min before celecoxib addition.
Statistics
Experiments determining cytotoxic IC 50 values were repeated twice by two independent researchers. Each experiment was conducted with a minimum of 3 replicates. For determining apoptosis, mitochondrial transmembrane potential, mitochondrial and cytosolic ROS levels, each experiment was repeated at least twice with a minimum of three replicates each time to determine mean values ± Standard Deviation (SD) unless otherwise indicated. N.D. = not determined. Statistical analysis was performed using Graphpad Prism (version 6.1) and Microcal Origin (version 8E) software and statistical significance was determined using ANOVA or standard Student's t-test.
Results
Celecoxib is a potent cytotoxic drug for metastatic melanoma and breast cancer cells, inducing extensive death by the mitochondrial apoptosis signalling pathway
A number of the NSAIDs are pro-drugs with critical Cys-thiol reactivity as one possible modality for activating the mitochondrial permeability pore and thereby inducing apoptosis of metastatic cancer cells [19] . However, the specific actions of NSAIDs on mitochondrial function and mechanisms for activating the intrinsic pathway of apoptosis in metastatic cancer cells have not yet been fully established.
In an initial study, five NSAIDs, including the third generation cyclooxygenase-2 (COX-2) selective celecoxib, were compared for doseand time-dependent cytotoxic activity against two murine metastatic cell lines, B16F10 melanoma and 4T1 breast cancer (IC 50 ; Table 1A) , as well as their growth inhibitory effects on several other metastatic, nonmetastatic and non-cancerous cell lines (GI 50 ; Fig. 1A , Table 1B) .
When compared to untreated cells across a concentration range 0-200 μM, celecoxib was clearly the most potent growth inhibitor of the five different NSAIDs (Fig. 1A) . Celecoxib also induced complete cell death in both B16F10 and 4T1 cells after 72 h at 100 μM concentration, with a dose-dependent increase in Sytox green signal detected as early as 24 h (Fig. 2A) . Celecoxib significantly diminished cell growth at 25 μM when given as a single dose over 72 h, whereas the other NSAIDs were much less potent as cytotoxic anticancer drugs (Table 1A & B) .
Cell growth assays were carried out comparing the GI 50 values for the NSAIDs, including celecoxib and its COX-2 independent derivative, dimethyl-celecoxib [33, 34] using a range of cell lines. At 24 h, celecoxib and dimethyl-celecoxib showed the highest levels of growth inhibitory activity against the two human metastatic breast cancer cell lines (MDA-MB-231 and MDA-MB-468; GI 50 = 6-27 μM) compared to other less sensitive cell lines (HeLa or MCF-7; GI 50 = 71-90 μM) (Table 1B) . Over the 24 to 72 h period, the GI 50 of celecoxib for the nonmalignant cells (normal 3T3 murine fibroblasts) was also higher (69-90 μM).
Next, B16F10 and 4T1 cells were exposed to each NSAID using its IC 50 /72 h concentration and apoptosis levels assayed after 24 h (Fig. 1C) . All of the NSAIDs increased the levels of apoptosis over the control (with the exception of salicylate that was assayed at the maximum concentration of 800 μM). On the basis of the above results, the five NSAIDs were then compared when applied using a fixed concentration of 50 μM for 48 h (Fig. 1D) . Again, celecoxib proved the most potent, causing extensive apoptosis by 48 h in both B16F10 and 4T1 cell lines (mean 63% and 67% apoptosis respectively).
To further assess for apoptosis, whole B16F10 and 4T1 cells were assayed and nuclear blebbing imaged using Sytox green as one indicator of apoptosis, as well as by using Acridine Orange staining to identify lysosomal formation, indicative of autophagy events. The concentration of celecoxib used (100 μM) was above the IC50 to ensure rapid activation of enhanced levels of apoptosis. Thus, apoptotic B16F10 cells with nuclear blebbing were detected by 24 h after treatment with 100 μM celecoxib ( Fig. 2A) . Even as early as 3 h after treatment with 100 μM celecoxib, Acridine Orange staining showed lysosomal formation indicative of autophagy, together with Sytox green nuclear blebbing and chromatin condensation indicating apoptosis ( Fig. 2B & C) . To confirm that celecoxib was inducing apoptosis via the mitochondrial signalling pathway, B16F10 cells were assayed for caspase 3/7 activity which increased significantly by 2-fold within 4 h of treatment with 100 μM celecoxib (Fig. 2D) . By 18 h of treatment with 100 μM of celecoxib, the level of caspase 3/7 activity had returned to that of the untreated controls, consistent with later stages of apoptosis. Hence, celecoxib rapidly induced mitochondrial mediated apoptosis, associated with increased signs of autophagy.
Selected NSAIDs rapidly induce significant increases in ROS production detected as mitochondrial superoxide in metastatic cancer cells
To further investigate the mechanisms for the NSAID-mediated toxicity on the metastatic B16F10 and 4T1 cancer cells, the ability of the NSAIDs to promote cellular ROS production was analysed. Exposing these two cell lines to 50 μM of each NSAID did not significantly change the endogenous levels of cytosolic ROS detected by DCFDA in the B16F10 cell line over 2-24 h of treatment (Fig. 3A) , with the exception of a significant salicylate-induced increase detected at 24 h. Slightly increased cytosolic ROS was obtained with 50 μM tert-butyl hydroperoxide (t-BHP) added as a positive control for producing ROS inside the cells. Hence, the present data indicate that cytosolic levels of ROS were not greatly affected by the NSAIDs. Next, ROS production at the mitochondrial level was analysed using the fluorescent indicator dye MitoSOX™red to detect mitochondrial superoxide [35] . Table 2A summarises the data for each of the NSAIDs, tested at different concentrations (as indicated) reflecting their IC 50 values for their abilities over the first hour after adding drug to promote mitochondrial ROS production. Of the NSAIDs, celecoxib was markedly more active at inducing significantly increased mitochondrial ROS production, even with low concentrations of added drug. These results were confirmed both by spectrophotometry (Fig. 3B) and fluorescence microscopy with celecoxib tested for 1 h over the range of 50-200 μM ( Fig. 3; Panel D) . Of the five NSAIDs, only celecoxib displayed such a markedly increased mitochondrial ROS signal above that of the control or vehicle alone treated cells.
Next, B16F10 cells were exposed to each individual NSAID fixed at 50 μM and the superoxide production levels assayed at regular 2 h intervals for up to 6 h. Alpha-tocopherol succinate (α-TOS), a known potent inducer of mitochondrial superoxide [36] , was included as a positive control for enhancing mitochondrial ROS production (Table 2A) . Celecoxib was the only NSAID that induced greater levels of mitochondrial superoxide production by 2 h (39% increase over control; Fig. 3C ). However, by 4 h, the celecoxib treated B16F10 cells showed substantially greater mitochondrial superoxide (137% increase above control cells; Fig. 3C ), with diclofenac then displaying a nonsignificant increase. By 6 h, all five of the NSAID-treated B16F10 samples started to show increased mitochondrial superoxide production, with both diclofenac and nimesulide induced levels then becoming significant (Fig. 3C, 103% and 118% increase respectively). By 6 h, the celecoxib induced levels of ROS production started decreasing, consistent with a transient oxidative burst of mitochondrial superoxide taking place.
To examine the NSAID induced mitochondrial superoxide production more closely, treated cell samples were assayed by flow cytometry at regular 6 min intervals for up to 84 min (Fig. 4A) . Celecoxib induced significant mitochondrial superoxide production in both the B16F10 and 4T1 metastatic cells, detected as early as 12 min after drug addition, becoming strongly significant in both cell lines by 84 min, when compared to untreated controls. Nimesulide was the only other NSAID that increased the levels of mitochondrial superoxide production over this time course, and only in the B16F10 cells (Fig. 4A) . These findings indicated that celecoxib at this concentration (50 μM) was able to rapidly induce mitochondrial superoxide production over short time periods, whereas the other NSAIDs have a more delayed mechanism of action, or are active only at much higher concentrations. To ensure that the superoxide signal observed with MitoSOXred was emanating from the mitochondria, high resolution confocal microscopy was performed after treatment with 100 μM celecoxib for 1 h. Image panels in Fig. 4C demonstrate greatly increased mitochondrial superoxide production detected as higher MitoSOXred signal as compared to untreated controls (Fig. 4B) . Moreover, nuclear DNA staining by dihydroethidium (DHE), which is produced after mitochondrial reaction of MitoSOXred with superoxide [37] , showed that as early as 1 h, translocation of DHE into the cell nuclei was visibly present (counterstained using DAPI; Fig. 4D ).
To identify whether the superoxide ROS signal obtained from celecoxib could be blocked and thereby prevent drug-induced apoptosis, both the B16F10 and 4T1 cell lines were pre-treated with the potent mitochondrial superoxide dismutase (SOD) mimetic, MnTMPyP [38] as a mitochondrial targeted antioxidant before addition of celecoxib for a further 2-4 h. T-BHP alone treated cells were used as a positive control for ROS production. MnTMPyP pre-treating cells before adding celecoxib inhibited the superoxide production levels in both cell lines, causing significant loss of the MitoSOXred signal at both the 2 and 4 h time points (Fig. 5A & B) . Furthermore, DHE staining in the cell nuclei was completely absent when cells were first pre-treated for 10 min with MnTMPyP before 2 h of celecoxib treatment (image panel; Fig. 5C ). Also, comparing the untreated versus celecoxib treated cells either with or without MnTMPyP pre-treatment, again showed a marked absence of nuclear DHE staining visible when the potent SOD mimetic was present ( Fig. 5D image panel) .
The pro-oxidative drug, α-TOS, was examined as a positive control for ROS as we had previously established that this drug promoted mitochondrial ROS production required to activate cancer cell apoptosis [36] . In line with our previous report, pre-treating B16F10 cells with MnTMPyP [50 μM] for 1 h inhibited the superoxide signal induced by α-TOS at 3 h (Fig. 6A, B) . Furthermore, pre-treating the B16F10 cells with MnTMPyP [50 μM] for 1 h also partially reversed the celecoxib [50 μM] induced level of cell death at 48 h from 40 to 20%, indicating that the mitochondrial ROS signal induced by celecoxib was required to activate cell death (Fig. 6B) . These findings confirm a requirement for the celecoxib-induced mitochondrial ROS in triggering subsequent cancer cell apoptosis.
Celecoxib inhibits respiration and Δψ m of human tumor cells
To examine the sensitivity of mitochondria in human metastatic cancer cell lines to celecoxib, the triple negative metastatic breast cancer lines MDA-MB-231 and MDA-MB-468 were used and the effects of up to 200 μM drug assayed on the respiratory rates (Table 2B) and Δψ m (Table 2C) in cultured whole cells. The results showed that the mitochondrial respiratory function in these metastatic human breast cancer cell lines was highly sensitive to the effects of this NSAID, even at the low μM range, consistent with the celecoxib concentrations required to inhibit the growth of these cells (Table 1B) . Next, the effect of celecoxib on either rhodamine 6G or tetramethylrhodamine, methyl ester (TMRM; results not shown) uptake was analysed as cell-permeant, cationic, red-orange fluorescent dyes readily sequestered by active mitochondria as indicators of the levels of mitochondrial transmembrane potential (Δψ m ) . Celecoxib addition also caused a decrease in Δψ m in a dose-dependent manner over the 5-20 μM range (Fig. 7A) , associated with inhibition of respiration, consistent with the severe decrease detected in cell proliferation (Table 1B) . The IC 50 values determined for the celecoxib mediated inhibition of Δψ m were low, at 6-6.7 μM for both of the MDA-MB-231 and MDA-MB-468 cell lines (Fig. 7A) . Celecoxib over similar concentrations inhibited OxPhos (i.e., oligomycin-sensitive respiration) (Table 2B ) and decreased Δψ m in the human metastatic breast cancer cell lines, as well as in the cervical adenocarcinoma HeLa cells (Table 2C) . Dimethylcelecoxib, the non-COX-2 analogue showed similar inhibitory effects on OxPhos and Δψ m of the triple negative breast cancer cell lines (Tables 2B and C) . 
Celecoxib directly induces ROS production from isolated mitochondria and inhibits the respiratory rates in cancer cells
The preceding results suggested that celecoxib could be directly affecting metastatic cell mitochondria, promoting their levels of ROS production. To further explore this possibility, purified mitochondria were isolated from fresh rat heart and liver or from AS-30D rat hepatocarcinoma ascites fluid as a ready source [29] and assayed for the direct effects of celecoxib on the mitochondrial respiratory rates and associated levels of ROS production. Celecoxib treatment of isolated rat liver mitochondria showed a dose-dependent inhibition of respiratory rates from State 3 and State 4 control values, particularly noticeable at higher concentrations of celecoxib (250-500 μM) and in short-term experiments of 2-5 min (Table 3) . Celecoxib inhibition was greater when mitochondria were respiring on glutamate + malate (G + M) with higher celecoxib concentrations (250 and 500 μM) causing 70-90% inhibition ( Table 3 ). The respiratory control ratios (state 3 rate/state 4 rate) were also significantly decreased by ∼50% at 100 μM celecoxib, across the different substrate conditions (Table 3) , consistent with an ensuing inhibition of Δψ m derived from proton leak/uncoupling and then respiratory chain inhibition occurring with successively higher amounts of added drug (Table 2C) . Increasing concentrations of celecoxib (0-500 μM) decreased the rat liver mitochondrial state 3 respiratory rate independently of the substrate used. Extending the treatment time by pre-incubating with drug (0-500 µM celecoxib, Table 4 ) for 15 min before measuring respiration rates did not show a greater inhibitory effect. Celecoxib was also highly active on heart mitochondria, particularly noticeable when succinate was included as substrate (either as G + M + S, or S + R). When succinate + rotenone (S + R) was used as substrate, celecoxib (250-500 μM) inhibited respiration by 70-80%. This result suggested a possible preference in heart mitochondria for inhibiting succinate driven Complex II function when celecoxib is at this higher concentration. In addition, the inhibitory effect of celecoxib at 250 μM on rat heart mitochondria State 3 respiration was not as marked when G + M (50% inhibition; n = 4) were used as substrates compared to succinate alone (S + R, 70-80%; Table 3 ). Heart mitochondrial State 4 respiration was unaltered even when higher celecoxib doses were applied. These data suggest that when mitochondria are isolated and removed from the context of normal cells, such that the cytosolic antioxidant defences are taken away, the mitochondria then become sensitive to the direct actions of celecoxib on respiration.
For mitochondria isolated from AS-30D hepatoma cells (Table 4) , celecoxib did not significantly change the State 3 and 4 respiration rates (particularly State 3 respiration, which is State 3 minus pseudo State 4), showing a slight decrease in State 3 at 50, 250 and 500 μM, with all substrates assayed. These results further indicated that isolated normal mitochondria are more susceptible to the effects of celecoxib than are Table 2C ). B) Celecoxib induced ROS production from isolated hepatoma mitochondria. Drug at concentrations as indicated was added directly to isolated AS-30D mitochondria whilst measuring basal ROS production by changes in absorbance of Amplex Red. Arrow indicates point of addition of celecoxib at concentrations indicated. C) Model for application of celecoxib as a chemosensitizing agent by inducing mitochondrial superoxide production (ROS) if combined with current commonly used chemo/radiotherapy based treatments to promote enhanced cancer cell death. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) the isolated tumor mitochondria. This difference in celecoxib sensitivity between mitochondria types (normal versus tumor) could be related to the higher content of cholesterol (20-times) found in the tumor mitochondrial membranes compared to rat liver mitochondria [39] . Cholesterol makes membranes more rigid which may interfere with drug transport and uptake into the mitochondrial matrix [40] .
Next, the effect of celecoxib on the level of ROS production from isolated AS-30D hepatocarcinoma cells as a ready source of tumor cell mitochondria were assayed using the sensitive Amplex red dye [41] . A rapid and significant dose-dependent increase in ROS production from the isolated mitochondria was immediately detected after celecoxib addition, increasing over the concentration range tested (up to 50 μM), compared to the negligible levels of ROS produced by untreated AS-30D mitochondria respiring on either G + M or S (Fig. 7B) . This increased ROS correlated well with the effects of celecoxib on the mitochondrial superoxide production observed in whole metastatic cancer cells over a similar concentration range (Fig. 4A) . Effects of celecoxib on ROS production were also observed with isolated liver and heart mitochondria respiring on G + M or S (data not shown). The latter data with Amplex Red confirms the results using MitoSOXred to detect ROS produced by mitochondria in whole cells (Figs. 3, 4 ) and together these findings are the first demonstration that celecoxib has rapid and direct effects on isolated mitochondrial ROS production, possibly mediated by modifying the activity of the respiratory complexes CI and/or CII. Table 3 Celecoxib effects on substrate oxidation of isolated rat liver or heart mitochondria.
Rat liver mitochondria (RLM)
Rat heart mitochondria (RHM) Preincubation with celecoxib at 37°C in KME buffer and after 15 min, respiration rates were determined. Abbreviations: G, glutamate 5 mM; M, malate 5 mM for RLM or malate 0.1 mM for AS-30D; S, succinate 0.5 mM; R, rotenone 2 μM. Pst 4, pseudo-state 4 (respiratory rate before adding ADP); St 3, state 3 respiration (ADPstimulated respiratory rate); St 4, state 4 respiration (ADP-exhausted respiratory rate); RC (respiratory control, St3/St4 ratio). Values show the mean of 2 for RLM pre-incubated with drug. AS-30D mitochondria were measured directly upon addition of drug and show mean ± S.D. of 3-4 independent preparations, unless otherwise indicated (mean of (2)).
Discussion
NSAID cytotoxicity on cancer cells
Given the frequently observed decreased incidence of cancer from longitudinal studies of patients using low doses of NSAIDs for analgesic purposes ( [20] [21] [22] [23] ) including preventing metastasis [25] , much interest has arisen concerning the use of NSAIDs as potential anticancer therapies. In fact, recent results from a Phase II study have exemplified the clinical potential of celecoxib as a drug which greatly enhances survival and complete responses in patients with advanced Stage IV metastatic colorectal cancers when celecoxib was used as a treatment in combination with the chemotherapy, Capecitabine [42] .
The five NSAIDs examined showed marked variation in their IC 50 values, although with the exception of salicylate, the other NSAIDs either decreased cell growth and/or increased cell death in a dose-and time-dependent fashion. Celecoxib was by far the most potent NSAID for inducing cell death in the range of metastatic cell lines tested here, including against human triple negative breast cancer cells, where it was active even at the low micromolar concentration. Diclofenac also induced cell death, although it required four-fold higher concentrations than celecoxib. Nimesulide restricted cell growth when at concentrations above 100 μM, but was not a significant inducer of cell death compared to either celecoxib or diclofenac. Both sulindac and salicylate only induced cell death at very high μM to low mM concentrations making these unlikely to be achievable or useful as a therapy in vivo.
In the present study, celecoxib showed marked activity against the human triple negative breast cancer cell lines, decreasing proliferation within 24 h when using low levels (GI 50 at 24 h was ∼6 μM for MDA-MB468; and ∼20 μM for MDA-MB231). In these studies, the metastatic cancer cells were only exposed to a single dose of drug added at the start of the assays, with monitoring over periods of 24-72 h. Repeated daily doses of low (1-10 μM) celecoxib levels administered to the metastatic cancer cells could sustain much higher accumulative drug actions and effects in vitro, with a greater net cytotoxic activity and further decrease IC 50 and GI 50 values in a system more closely mimicking an in vivo dosing regimen [43] . In this regard, low and physiologically relevant levels (1-10 μM) of celecoxib have been reported to chemosensitize cancer cells to subsequent treatment with common cytotoxic chemotherapeutic drugs such as doxorubicin [44, 45] and greatly enhances chemotherapeutic anti-metastatic cancer cell efficacy in vitro and in vivo [44, 46] , as well as in clinical trials of metastatic colorectal cancer patients [42] .
Celecoxib induces mitochondrial ROS production required for triggering cancer cell death by apoptosis
Our novel findings reported here clearly highlight previously unrecognised effects of the NSAIDs such as celecoxib on mitochondrial respiration and function. The data presented here establish that celecoxib is a potent anticancer agent which can directly and rapidly affect mitochondrial O 2 uptake by causing excessive mitochondrial superoxide production. This pro-oxidative activity of celecoxib is essentially required for the triggering of extensive cell death via the intrinsic apoptotic pathway because its action is prevented by pre-treating cells with the potent anti-oxidative SOD mimetic, MnTMPyP. These findings of excessive mitochondrial ROS production explain the previously reported celecoxib mediated mechanism of action inside cancer cells shown to proceed via the mitochondrial apoptosis signalling pathway [47] . Results from other studies are entirely consistent with our own findings presented here that celecoxib is cytotoxic for cancer cells independent of its effects on COX-2 [48, 49] , particularly for the closely related, COX-2 non-inhibitory analogue, dimethylcelecoxib, which shows even greater anticancer activity [50] [51] [52] . Our results establish that celecoxib increases mitochondrial ROS levels to trigger the ensuing cytotoxic actions of the drug, activating the intrinsic apoptotic pathway in metastatic cancer cells by disrupting mitochondrial metabolism and induces excessive ROS production directly from the mitochondria as an essential part of this death signalling process.
Celecoxib promotes mitochondrial ROS production at levels below those inhibiting respiratory function
This is the first report demonstrating the mechanism for the direct actions of celecoxib on mitochondria, either isolated or inside cells, showing in both situations that the drug induces rapid ROS production at lower doses of drug (5-50 μM) than those required to inhibit respiratory rates (> 100 μM), when either Complex I or II substrates are available for use. In addition, the ability of celecoxib to inhibit respiration was greater for State 3 respiration (i.e., oxidative phosphorylation) under conditions where succinate was present. Interactions of celecoxib with the respiratory chain complexes involving either the FAD or a ubisemiquinone intermediate could be sources for the ROS production proceeding via electron leakage from the complexes interacting with molecular O 2 to form superoxide [53] .
Celecoxib at concentrations of less than 50 μM was clearly superior to other NSAIDs tested for their anti-metastatic cancer cell cytotoxicity and this activity correlated well with ROS production levels. The ability of celecoxib to inhibit the Δψ m would also suggest that inhibiting the respiratory chain function, in a manner similar to that of the Complex III inhibitor Antimycin A [54] facilitates collapse of the mitochondrial transmembrane potential in the metastatic cancer cells. The combined effects of ROS and loss of Δψ m most likely contribute to inducing the ensuing intrinsic apoptosis pathway in celecoxib treated metastatic cancer cells.
Clinical relevance of celecoxib anti-cancer activity to drug pharmacokinetics in humans
We have included a table of recommended NSAID dosage per day, resulting peak serum concentrations, calculated maximum available concentrations (μM values) and source references (Table 5) , particularly relating to celecoxib in humans. Based on this data, levels of celecoxib can be achieved in the 10-20 μM range which are sufficient and capable of effectively killing cancer cells in vivo. Analysis of peak plasma concentrations for celecoxib from patients taking daily doses (400 mg) for rheumatoid arthritis (RA) and (800 mg, as a 400 mg does * Cmax (μM) values are calculated based on the maximum allowable single dosage and peak plasma (Cmax; μg/mL) corresponding to that dosage.
taken twice-daily) for familial adenomatous polyposis (FAP) after 3-4 h reached ∼4 μM and ∼8 μM respectively [55] . Peak levels depend on patient CYP2A9 versus CYP2C8 polymorphisms of the cytochrome P450 oxidases which metabolise celecoxib [56] . Interestingly, patients given 200-mg celecoxib + 200-mg ketoconazole daily for 7 days to inhibit CYP enzymes showed the highest Cmax 12 μM, with no side effects [55] . More recent advances in drug delivery based around mixtures of polyvinylpyrolidone (PVP)/d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) as solid dispersion nanoparticles [57] or supersaturating self-emulsifying drug delivery systems (S-SEDDS) [58] have significantly increased the dissolution and orally administered bioavailability of celecoxib. The area under the concentration-time curve (AUC 0 → 24 h) and peak plasma concentration (Cmax) was increased several fold using celecoxib-PVP-TPGS formulations [57] or S-SEDDS with the highest Cmax reaching 8 μg/ml (or 20 μM) in rat plasma after 3-4 h [58, 59] . The human equivalent dose (HED) based on the FDA guidelines for body area would be 16 mg/kg or 800 mg/day for a 50 kg person. Recently, a liquid formulation of celecoxib (aka DFN-15) was developed which gave improved median time to peak concentration (Tmax) within 1 h whereas 2.5 h was required for the oral capsules [60] . The pharmacokinetics of DFN-15 was dose proportional over the range tested (120-240 mg) and the Cmax after administering DFN-15 at 120, 180, and 240 mg (1062-1933 ng/ml; 2.7-5 μM) were much higher than for the 400 mg oral capsules (611 ng/ml) [60] . However, 400 mg oral capsules provided higher sustained levels over 72 h with AUC (8 μg h/ml). Given the IC 50 for celecoxib obtained in the present study of 25-30 μM after 96 h, reaching the range of physiologically relevant plasma concentrations should be achievable and tolerable over one to two weeks of treatment. In addition, considering that the present study was based on the use of only a single dose with monitoring over 72-96 h, it is probable that a treatment regime using repeated daily dosing over several days of up to 800 mg would bring the concentration of celecoxib to within the 10-20 μM range, in line with clinically relevant values. Furthermore, with celecoxib demonstrating a significant killing of both cell lines at ∼10 μM from a single dose, then such a repeated daily dosing scheme (400 mg capsule twice-daily) should provide levels sufficient for killing in vivo. In this regard, it should be noted that many studies have reported use of celecoxib doses at these levels as an adjunct therapy in combination with common chemotherapeutic drugs (such as doxorubicin or 5-flurouracil). Several trials have demonstrated synergism with either a marked decrease in the levels of chemotherapy required to be effective or enhanced anticancer efficacy when given as combination therapy for advanced stage metastatic cancers [44, [61] [62] [63] [64] [65] [66] . Mitochondrial targeted anticancer drugs (Mitocans) can be considered as promising to help eradicate chemotherapy resistant cancer cells because they directly promote pro-oxidative stress to affect mitochondria independent of upstream signalling events and offer new perspectives for developing innovative and more effective combinatorial cancer therapies [1] . The COX-2 independent effects of celecoxib are shown here as directly inducing increased mitochondrial ROS production to enhance death of metastatic cancer cells. This finding provides the supportive mechanistic evidence justifying using celecoxib as an approved pharmaceutical either as a standalone or in combination treatment for the eradication of metastatic lesions, as has been shown previously in vivo or in clinical trials now in many studies [44, [67] [68] [69] [70] [71] , and as summarized in Fig. 7C . The duality of such treatments should result in better patient outcomes and remission rates [42] , but also help to reduce the toxicities of chemotherapy and may decrease the relative amounts of drugs that are required.
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